Co-Targeting of MDM2 and CDK4/6 with Siremadlin and Ribociclib for the Treatment of Patients with Well-Differentiated or Dedifferentiated Liposarcoma: Results from a Proof-of-Concept, Phase Ib Study
Journal
Clinical cancer research : an official journal of the American Association for Cancer Research
Journal Volume
28
Journal Issue
6
Date Issued
2022-03-15
Author(s)
Abdul Razak, Albiruni R
Bauer, Sebastian
Suarez, Cristina
Quek, Richard
Hütter-Krönke, Marie Luise
Cubedo, Ricardo
Ferretti, Stephane
Guerreiro, Nelson
Jullion, Astrid
Orlando, Elena J
Clementi, Giorgia
Sand Dejmek, Janna
Halilovic, Ensar
Fabre, Claire
Blay, Jean-Yves
Italiano, Antoine
Abstract
Well-differentiated (WDLPS) and dedifferentiated (DDLPS) liposarcoma are characterized by co-amplification of the murine double minute-2 (MDM2) and cyclin-dependent kinase-4 (CDK4) oncogenes. Siremadlin, a p53-MDM2 inhibitor, was combined with ribociclib, a CDK4/6 inhibitor, in patients with locally advanced/metastatic WDLPS or DDLPS who had radiologically progressed on, or despite, prior systemic therapy.
Type
journal article